This review will highlight recent developments in mineralocorticoid receptor research which impact aldosterone-associated vascular and cardiometabolic dysfunction.
INTRODUCTION
Blockade of the rennin-angiotensin-aldosterone system (RAAS) is the most effective strategy for the prevention of renal disease progression, heart failure, and cardiovascular death. A portion of these beneficial effects can be attributed to aldosterone reduction or mineralocorticoid receptor antagonism, with beneficial effects beyond hypertension control, such as improvements in glucose metabolism, fibrosis, and inflammation. Although the extra-renal effects of aldosterone and the mineralocorticoid receptor have been well demonstrated within cardiac tissues, specific actions within the vascular endothelium and smooth muscle have recently been demonstrated. The purpose of this review is to summarize developments in the literature pertaining to aldosterone, and vascular and metabolic dysfunction.
ADIPOCYTES SECRETE ALDOSTERONE-STIMULATING FACTORS
The association between adipose mass and increased plasma aldosterone concentration has been demonstrated in diverse populations, leading to the hypothesis that circulating adipocyte-derived factors stimulate aldosterone secretion [1] . This is supported by in vitro studies, where the transfer of culture media from adipocyte to adrenal cell culture stimulates aldosterone secretion to the same magnitude as angiotensin II, but is not prevented by angiotensin receptor blockade [2] . Recently in the Multi-Ethnic Study of Atherosclerosis, plasma adiponectin associated negatively and leptin associated positively with plasma aldosterone concentration in 1970 patients, free of cardiovascular disease, suggesting that these adipokines could also alter aldosterone secretion [3] . Functional leptin receptors are present on zona glomerulosa cells, and leptin stimulates aldosterone production in vitro in human adrenocortical cells and in vivo in mice, demonstrating that leptin may be a significant mediator of obesity-associated hyperaldosteronism. These effects are mediated via the leptin receptor and are independent of angiotensin II or adrenergic activation [4] . Leptin-stimulated aldosterone secretion may also explain the elevated aldosterone concentration in patients with obesity and metabolic syndrome [5] and the decreased concentration after weight loss [6] (Fig. 1 ). Because leptin increases in direct proportion to fat mass, it may be an additional link between obesity, hypertension, and metabolic syndrome.
MINERALOCORTICOID RECEPTOR OVEREXPRESSION IN ADIPOCYTES INTERRUPTS GLYCEMIC AND BLOOD PRESSURE CONTROL
Conversely, aldosterone directly stimulates adipocyte expansion, increases leptin expression, and impairs adipocyte function in culture systems [7,8 && ]. Decreased circulating adiponectin concentration is associated with insulin resistance, obesity, and endothelial dysfunction [9] . Aldosterone decreases adiponectin expression in adipocyte culture, and mineralocorticoid receptor antagonism normalizes adiponectin and decreases adipocyte macrophage infiltration and inflammatory cytokines in obese diabetic db/db mice [10] . Multiple studies have also demonstrated that aldosterone impairs insulin sensitivity via mineralocorticoid receptor activation in adipocytes in vitro [11, 12] . Nevertheless, obesity and insulin resistance develop during highfat feeding in aldosterone synthase deficient mice, although diet-induced changes in glycemia, hepatic steatosis, adipocyte macrophage inflammation, and plasma high-molecular weight adiponectin are attenuated [13] . Obesity is also associated with increased mineralocorticoid receptor expression in subcutaneous and visceral fat and in mature adipose fractions in humans and in mice [8 && ]. In the same investigation, doxycycline-induced adipocyte mineralocorticoid receptor-overexpression for 12 weeks was found to cause metabolic syndrome-like alterations in visceral fat, glucose tolerance, triglyceridemia, and cholesterolemia without altering circulating aldosterone or blood pressure. Furthermore, lipocalcin-like prostaglandin D2 synthase (PTGDS) increases during mineralocorticoid receptor activation by overexpression in vivo or by aldosterone or glucocorticoid incubation in vitro. PTGDS inhibition with AT56 prevents aldosterone-induced adipogenesis and insulin resistance in vitro, demonstrating a novel mineralocorticoid receptor-dependent pathway which may impair systemic metabolism [8 && ]. These studies demonstrate that adipocytederived factors can stimulate aldosterone secretion, and, in turn, aldosterone may cause adipocyte dysfunction and adverse metabolic consequences.
EFFECTS OF ALDOSTERONE ON VASCULAR INFLAMMATION AND FUNCTION
Obesity, metabolic syndrome, and diabetes are associated with markedly increased cardiovascular risk, and aldosterone has been linked as a potential mediator. Experimental aldosterone administration
KEY POINTS
Vascular endothelial mineralocorticoid receptor prevents vascular thrombosis, whereas vascular smooth muscle mineralocorticoid receptor contributes to hypertension and smooth muscle hypertrophy.
Adipocyte-derived leptin stimulates aldosterone secretion, and adipocyte mineralocorticoid receptor activation produces the metabolic syndrome phenotype.
Novel nonsteroidal mineralocorticoid receptor antagonists demonstrate promising effects in diabetic nephropathy and may reduce hyperkalemia risk. causes perivascular inflammation and fibrosis, whereas mineralocorticoid receptor antagonism prevents this injury. Angiotensin II administration produces a similar pattern of injury, which is prevented in part by adrenalectomy, mineralocorticoid receptor antagonism, or aldosterone synthase inhibition or deficiency [14] [15] [16] [17] . During a high-fat/ high-carbohydrate diet (Western diet), mice develop obesity and vascular remodeling with vascular endothelial and smooth muscle cell stiffness, aortic medial hypertrophy, periaortic inflammation, and impaired vasodilation. In this model, spironolactone prevents Western diet-induced vascular remodeling and vascular dysfunction, even though it does not prevent obesity, systemic insulin resistance or hyperglycemia [18] . This study significantly expands the literature by demonstrating that spironolactone also prevents proinflammatory M1 macrophage infiltration in the aorta, shifting the balance toward an anti-inflammatory M2 phenotype with increased interleukin-10 production [18] .
Since the initial demonstration that targeted mineralocorticoid receptor deletion within vascular smooth muscle attenuates age-related hypertension [19] , additional studies have continued to dissect the role of the mineralocorticoid receptor within the vascular endothelium and vascular smooth muscle in vivo [20, 21] . After a short period of aldosterone (8 days) endothelial cell mineralocorticoid receptor deletion (EC-MRKO) preserves acetylcholinestimulated nitric oxide-dependent vasodilation in the aorta but not mesenteric vessels, suggesting a specific role in conduit arteries. After deoxycorticosterone/salt treatment for 8 weeks, EC-MRKO was similarly protected against increased cardiac intercellular adhesion molecule 1, macrophage infiltration, inducible nitric oxide synthase, and collagen deposition, even though the blood pressure response was not significantly altered [21] . In contrast, mineralocorticoid receptor overexpression in vascular endothelial cells (MR-EC) confers protection against ferric-chloride-induced carotid artery thrombosis, which is mediated in part via increased von Willebrand factor release and endothelial protein C receptor (EPCR) expression [22 & ]. Systemic blood pressure and pressor response to multiple vasoconstrictors are also increased in these MR-EC mice [23] . The authors hypothesize that a healthy vascular endothelium is essential for the antithrombotic effects of vascular endothelial mineralocorticoid receptor activation, whereas aldosterone exerts prothrombotic effects in the presence of endothelial injury [22 & ]. The vascular smooth muscle mineralocorticoid receptor has complementary but independent effects on vasculature function, which have been recently delineated. Inducible, targeted mineralocorticoid receptor deletion from smooth muscle cells (SMC-MR, derived from SMA-Cre-ER T2 line) reduces vascular myogenic tone and systemic blood pressure with ageing and reduces oxidative stress and hypertension during angiotensin II infusion [19] . After wire-induced carotid injury, mineralocorticoid receptor deletion also prevents aldosteroneaugmented vascular smooth muscle proliferation and vascular fibrosis [24 && ]. Vascular endothelial growth factor receptor1 (VEGFR1) expression increases in vascular smooth muscle after vessel injury, and VEGFR1 blockade prevents fibrosis and vascular smooth muscle proliferation in a blood pressure independent manner [24 && ]. Placental growth factor (PlGF) likely contributes to this injury because it increases in response to aldosterone and it binds specifically to VEGFR1 [24 && ,25]. Other investigators have created a constitutive vascular smooth muscle mineralocorticoid receptor knockout (mineralocorticoid receptor SMKO , derived by crossing with the SM22-Cre line) which develops no alterations in renal sodium handling [26] . After 4 weeks of nephrectomy/aldosterone/salt, blood pressure increases similarly in mineralocorticoid receptor SMKO mice, but mineralocorticoid receptor deletion preserves carotid artery distensibility, reduces a5-integrins, and increases a1-integrin expression.
These studies demonstrate that aldosterone and the vascular mineralocorticoid receptor contribute to vascular dysfunction and remodeling independent of blood pressure and renal sodium handling, but the endothelial mineralocorticoid receptor may also have protective antithrombotic effects. These studies also highlight the specific endothelial (e.g., increased cardiac intercellular adhesion molecule 1, EPCR, von Willebrand factor) and vascular smooth muscle mineralocorticoid receptor-dependent genes (PlGF, TNFa).
EFFECT OF MINERALOCORTICOID RECEPTOR ANTAGONISM ON CORONARY FLOW RESERVE
The vascular effects of mineralocorticoid receptor antagonists have been most prominently demonstrated in patients with atherosclerotic heart disease and heart failure, including those with type 2 diabetes mellitus (T2DM). Coronary flow reserve reflects cardiac microvascular function, and has been associated with increased cardiovascular risk in T2DM patients even in the absence of obstructive coronary artery disease. Two studies recently examined the effect of spironolactone on coronary flow reserve. Garg et al. [27] performed a randomized, double-blind study of 64 patients with T2DM, and no evidence of cardiac ischemia by positron emission tomography imaging was found. After washout of other antihypertensive medications and a run-in period on enalapril therapy, patients were treated with either spironolactone 25 mg, hydrochlorothiazide 12.5 mg, or placebo daily for 6 months. Spironolactone 25 mg daily significantly increased coronary flow reserve compared with the other groups [27] , despite a similar reduction in blood pressure between the spironolactone and hydrochlorothiazide groups. However, no significant differences in resting echocardiographic measures were observed during the course of treatment.
Bavry et al. [28] performed a randomized doubleblind placebo controlled trial in 41 patients with nonobstructive coronary artery disease. After a baseline coronary angiogram, patients were randomized to eplerenone 25 mg for 4 weeks and then 50 mg for 12 weeks before returning for a repeat coronary angiogram. Coronary vascular response was measured after adenosine, acetylcholine, and nitroglycerin. As opposed to the previous study, there was no significant difference between eplerenone and placebo. In a post-hoc analysis, however, eplerenone tended to improve coronary vasodilation in patients with the most severe dysfunction at baseline. These two studies differ in study population, standardized treatment, treatment duration, and method of assessment of coronary endothelial function which could explain the differing results.
EFFECTS OF MINERALOCORTICOID RECEPTOR ON CARDIOVASCULAR INFLAMMATION
Vascular inflammation and fibrosis are prominent features of mineralocorticoid-induced hypertension. Deletion of the macrophage/monocyte mineralocorticoid receptor (Mac-MRKO) has been shown to ameliorate vascular inflammation hypertension, plasminogen activator inhibitor-1 expression, and fibrosis in mineralocorticoid receptordependent and mineralocorticoid receptor-independent models [29, 30] . As noted above, the EC-MRKO mice are protected against cardiovascular inflammatory cell infiltration and fibrosis. In contrast, macrophage infiltration in response to mineralocorticoid hypertension is intact in Mac-MRKO but inflammatory and fibrotic responses (e.g., PAI-1) are attenuated [30] . In myeloid-specific mineralocorticoid receptor knockout mice (MyMRKO), macrophage polarization is alternatively activated by PPARg or glucocorticoids [31] . The finding that spironolactone shifts the Western diet-induced M1 macrophage toward an M2 phenotype demonstrates that this response may be altered using conventional pharmacologic means [18] . This mechanism could contribute to the observed reduction in cardiovascular complications during spironolactone treatment.
ROLE OF MINERALOCORTICOID RECEPTOR ANTAGONISM IN PREVENTION OF DIABETIC NEPHROPATHY
Although RAAS blockade reduces the risk of diabetic nephropathy progression, the number of patients who progress to renal failure remains unacceptable. Annual Medicare costs for end-stage renal disease are approximately $30 billion, accounting for 5.6% of the total Medicare budget [32] . Therefore, new approaches are urgently needed not only to improve clinical outcomes but to reduce annual Medicare costs. One potentially beneficial approach is the use of mineralocorticoid receptor antagonist (MRAs), which prevent renal injury in multiple renal injury models and reduce proteinuria in small clinical studies [33] [34] [35] . However, their effect on long-term outcomes has not been proven, and the risk of hyperkalemia with spironolactone and eplerenone has limited the enthusiasm for their use in high-risk conditions, such as diabetic nephropathy [35] .
Recently, a new class of nonsteroidal MRAs was discovered. Their development and early clinical studies have been reviewed previously, and several drugs have advanced into clinical trials [36, 37] . As opposed to most diuretic agents, MRAs do not require filtration to reach their renal epithelial target, and therefore would not be anticipated to lose effectiveness in renal insufficiency. However, this potential benefit must be weighed against the increased risk of hyperkalemia. Nonsteroidal MRAs, including finerenone, reduce proteinuria in rodents with a lower incidence of hyperkalemia compared to steroidal MRAs [36, 37] . Finerenone has advanced the furthest in clinical trials for the treatment of diabetic nephropathy, and for heart failure with diabetes or chronic kidney disease (CKD) [38 && ,39,40] . The Miner Alocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN; NCT01874431) recently reported on the results of this randomized, double-blind, placebocontrolled, parallel-group study. The primary outcome is effect of finerenone on the risk of hyperkalemia and the biomarker outcome of albuminuria reduction [urine albumin/creatinine ratio (UACR)]. Finerenone treatment was given as 1.25, 2.5, 5, 7.5, 10, 15, or 20 mg daily of finerenone added onto standard RAAS blockade with either angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) for 3 months. A total of 823 total patients were randomized, and 764 completed the treatment.
Finerenone demonstrated a dose-dependent reduction of albuminuria after 3 months, without reaching a clear plateau at the maximum dose of 20 mg daily (0.62 ratio of day 90 vs. baseline UACR). A greater proportion of patients treated with finerenone 20 mg daily had a !50% reduction of UACR compared with placebo (40.2 vs. 13.6%; P < 0.001). This degree of albuminuria reduction is comparable with the reduction of 34% with spironolactone 25 mg daily added to lisinopril 80 mg daily [35] . Statistical significance for albuminuria reduction was reached for doses of 7.5, 10, 15, and 20 mg once daily, and future studies will likely use doses in this range to test long-term benefit. These doses are consistent with early analyses of the ARTS-Heart Failure (HF) study which demonstrate an optimal dose of 10-20 mg daily.
The main concern regarding these agents is hyperkalemia, especially in patients at high risk because of diabetes and CKD who are already receiving maximal ACE-I or ARB treatment. In the ARTS-DN study, 1.8% of patients receiving an effective finerenone dose (7.5-20 mg) had documented serum K ! 5.6 mmol/l, and one patient in this group had a serum K ! 6.0 mmol/l. On average, finerenone 20 mg increased serum potassium by 0.17 AE 0.46 mmol/l at 90 days, whereas no change was observed in the placebo group. In the subgroup with a baseline eGFR of 30-60 ml/min/1.73 m 2 , potassium increased by 0.30 AE 0.44 with finerenone 20 mg daily versus 0.04 AE 0.44 mEq/l with placebo. Although the risk for hyperkalemia in ARTS-DN was minimized by discontinuing potassium supplements and other drugs which may increase potassium, patients were not provided specific dietary potassium recommendations at study entry. The majority of patients in the study, including 86% of those on high-dose finerenone, received loop or thiazide diuretics which should reduce the hyperkalemia risk. In addition, RAAS blockade was maximized in 40.8% of patients, with 24.8% of patients receiving the minimum recommended dose. The effects of finerenone on colonic potassium handling are also unknown, whereas this mechanism assumes a significant importance in patients with advanced renal disease. Future phase III studies will hopefully better define the hyperkalemia risk of finerenone, in addition to testing the effectiveness for definitive renal endpoints when combined with protocolized, full-dose ACE-I or ARB therapy. Additional studies are ongoing to investigate the benefit of spironolactone on cardiovascular outcomes in patients with CKD [41] .
CONCLUSION
New investigations in the past year have significantly advanced our understanding of the extrarenal effects of aldosterone within the vascular endothelium, vascular smooth muscle, adipocytes, and macrophages. These findings suggest that the benefits of mineralocorticoid receptor antagonists in clinical trials could be mediated by these extrarenal mineralocorticoid receptor effects. Additional studies are ongoing to determine if the beneficial effects of mineralocorticoid receptor antagonists can be dissociated from the hyperkalemia risk, with novel nonsteroidal mineralocorticoid receptor antagonists providing some promising results for the prevention of diabetic nephropathy.
